A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.
- 21 Apr 2017 Planned initiation date changed from 1 Apr 2016 to 1 Apr 2017.
- 13 Apr 2016 New trial record